ResearcherKarolinska University HospitalNo recent work listed

Håkan Mellstedt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6756-0609; OpenAlex author ID A5069881022. Sources: ClinicalTrials.gov.

Their work

Papers: 2
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper

Papers 2

Trials 1

Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer Principal investigator NCT01547260 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Maria Liljefors · 2 shared papers, 2014–2017 · strength 0.14
- Paper Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. DOI 10.1371/journal.pone.0169736 ↗
- Paper Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. DOI 10.3892/ijo.2014.2496 ↗
Gustav Jörgen Ullenhag · 1 shared paper, 2017 · strength 0.09
- Paper Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. DOI 10.1371/journal.pone.0169736 ↗
Caroline Staff · 1 shared paper, 2014 · strength 0.06
- Paper Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. DOI 10.3892/ijo.2014.2496 ↗
Jan‐Erik Frödin · 1 shared paper, 2014 · strength 0.06
- Paper Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. DOI 10.3892/ijo.2014.2496 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.